| Verifiedrevid: | 461481983 |
| Width: | 240 |
| Tradename: | Ohtuvayre |
| Dailymedid: | Ensifentrine |
| Routes Of Administration: | Inhalation |
| Class: | PDE3 inhibitor/PDE4 inhibitor |
| Atc Prefix: | None |
| Legal Us: | Rx-only |
| Legal Us Comment: | [1] |
| Cas Number: | 298680-25-8 |
| Unii: | 3E3D8T1GIX |
| Cas Supplemental: | E-isomer: 1884461-72-6 |
| Pubchem: | 9934746 |
| Kegg: | D11743 |
| Chemspiderid: | 8110374 |
| Stdinchi: | 1S/C26H31N5O4/c1-15-10-16(2)24(17(3)11-15)29-23-14-20-19-13-22(35-5)21(34-4)12-18(19)6-8-30(20)26(33)31(23)9-7-28-25(27)32/h10-14H,6-9H2,1-5H3,(H3,27,28,32)/b29-23+ |
| Stdinchikey: | CSOBIBXVIYAXFM-BYNJWEBRSA-N |
| Synonyms: | RPL-554, LS-193,855 |
| Iupac Name: | N- |
| C: | 26 |
| H: | 31 |
| N: | 5 |
| O: | 4 |
| Smiles: | Cc3cc(C)cc(C)c3N=c2cc1-c(cc4OC)c(cc4OC)CCn1c(=O)n2CCNC(N)=O |
Ensifentrine, sold under the brand name Ohtuvayre, is a medication used for the treatment of chronic obstructive pulmonary disease (COPD) in adults. It is a phosphodiesterase 3 inhibitor and phosphodiesterase 4 inhibitor. It is given by inhalation.
It is an analog of trequinsin and, like trequinsin, is a highly selective inhibitor of the phosphodiesterase enzyme, PDE3; indeed, it is >3000-times more potent against PDE3 than PDE4.[2] As of October 2015, inhaled RPL-554 delivered via a nebulizer was in development for COPD and had been studied in asthma.[3]
PDE3 inhibitors act as bronchodilators, while PDE4 inhibitors have an anti-inflammatory effect.[2] [4]
Ensifentrine is indicated for the maintenance treatment of chronic obstructive pulmonary disease in adults.
Ensifentrine was part of a family of compounds invented by Sir David Jack, former head of R&D for GlaxoSmithKline, and Alexander Oxford, a medicinal chemist; the patents on their work were assigned to Vernalis plc.[5] [6] [7]
In 2005, Rhinopharma Ltd, acquired the rights to the intellectual property from Vernalis.[7] Rhinopharma was a startup founded in Vancouver, Canada in 2004 by Michael Walker, Clive Page, and David Saint, to discover and develop drugs for chronic respiratory diseases,[7] and intended to develop ensifentrine, delivered with an inhaler, first for allergic rhinitis, then asthma, then for COPD.[7] Ensifentrine was synthesized at a contract research organization, under the supervision of Oxford, and was studied in collaboration with Page's lab at King’s College, London.[2] In 2006 Rhinopharma recapitalized and was renamed Verona Pharma plc.[7]
Ensifentrine was approved for medical use in the United States in June 2024.[8]